BUFORD, Ga.--(BUSINESS WIRE)--July 19, 2006--Theragenics Corporation® (NYSE: TGX - News), a medical device company serving the prostate cancer treatment and surgical markets, today announced consolidated financial results for the second quarter ended July 2, 2006. Consolidated revenue for the quarter was $12.6 million compared to $11.4 million in the second quarter of 2005, an increase of 10.5%. For the six-month period, consolidated revenue was $25.0 million, compared to $20.9 million in the same period last year, an increase of 19.6%. Net income for the quarter was $433,000, or $0.01 per share, compared to a net loss of $1.0 million, or $0.03 per share in the second quarter of 2005. For the six-month period, net income was $1.2 million, or $0.04 per share, compared to a net loss of $1.5 million, or $0.05 per share, in 2005. The 2006 periods include the results of operations of CP Medical. The 2005 periods include the results of operations of CP Medical subsequent to its acquisition by Theragenics on May 6, 2005.
